As treatment strategies for early triple-negative breast cancer continue to evolve, translating clinical evidence into practice can be challenging, especially as the standard of care also shifts and may differ across studies. The management of patients with triple-negative breast cancer who have residual disease after neoadjuvant therapy exemplifies a complex clinical scenario with emerging yet sometimes difficult-to-interpret evidence. Through a critical appraisal of current data and an expert consensus discussion from the Nordic region, the authors present a perspective on postneoadjuvant treatment options for triple-negative breast cancer and discuss potential approaches based on available evidence and expert opinion.
Valachis et al. (Wed,) studied this question.